16 completed, 3 terminated, 1 active not recruiting, 1 withdrawn. 13 Phase 2, 7 Phase 1, 2 Not applicable, 1 Phase 3, 1 Phase 4.
Follow Burkitt's Lymphoma: new trials by email Literature Review of Burkitt's Lymphoma trials Research Report on Burkitt's Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| 19(T2)28z1xx Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Cancers 19(T2)28z1xx CAR T cells - Diffuse Large B Cell Lymphoma, Primary Mediastinal Large B Cell Lymphoma | Phase 1 | Active not recruiting | Memorial Sloan Kettering Cancer Center | 30 | 2020-07-06 | 2026-08-27 |
| UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep Fludarabine, Cyclophosphamide, MMF - Acute Leukemia, Acute Myeloid Leukemia | Phase 2 | Completed | Masonic Cancer Center, University of Minnesota | 15 | 2017-05-15 | 2025-07-04 |
| Allo HSCT Using RIC for Hematological Diseases Allopurinol, Fludarabine, Cyclophosphamide - Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia | Phase 2 | Completed | Masonic Cancer Center, University of Minnesota | 156 | 2017-03-09 | 2023-09-21 |
| Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases Fludarabine, Cyclophosphamide, Total Body Irradiation - Acute Myeloid Leukemia (AML), Acute Lymphocytic Leukemia (ALL) | Not applicable | Terminated | Masonic Cancer Center, University of Minnesota | 200 | 2016-12-01 | 2026-05-20 |
| Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Non Hodgkin Lymphoma (B-NHL) ADCT-402 - Non-Hodgkin Lymphoma, Burkitt's Lymphoma | Phase 1 | Completed | ADC Therapeutics S.A. | 183 | 2016-03-01 | 2021-05-19 |
| Reduced Intensity Conditioning and Haploidentical Related Bone Marrow for Patients With Hematologic Diseases Fludarabine, Cyclophosphamide, Total Body Irradiation - Acute Leukemias, Burkitt's Lymphoma | Not applicable | Terminated | Masonic Cancer Center, University of Minnesota | 2 | 2014-10-01 | 2019-12-26 |
| T-Regulatory Cell and CD3 Depleted Double Umbilical Cord Blood Transplantation in Hematologic Malignancies Treg cells, CD3+ Teff cells, Fludarabine - Hematologic Malignancy, Acute Myeloid Leukemia | Phase 1 / Phase 2 | Withdrawn | Masonic Cancer Center, University of Minnesota | 2014-01-01 | 2017-12-02 | |
| Retrospective Analysis of Rituximab-containing Immunochemotherapy for Burkitt's or Burkitt-like Lymphoma in Adults No intervention (observational study) - Burkitt's Lymphoma, High-grade B-cell Lymphoma | Completed | Gachon University Gil Medical Center | 43 | 2013-02-01 | 2017-02-24 | |
| Treatment for Advanced B-Cell Lymphoma Rituximab, IT Cytarabine - Diffuse Large Cell Lymphoma, Burkitt's Lymphoma | Phase 2 | Completed | New York Medical College | 45 | 2013-01-01 | 2022-10-25 |
| Double Cord Versus Haploidentical (BMT CTN 1101) Haploidentical Bone Marrow Transplant, Double Umbilical Cord Blood Transplant - Acute Lymphocytic Leukemia, Acute Myelogenous Leukemia | Phase 3 | Completed | Medical College of Wisconsin | 368 | 2012-06-01 | 2021-12-01 |
| Safety and Tolerability of HSC835 in Patients With Hematological Malignancies HSC835 - Acute Myelocytic Leukemia, Acute Lymphocytic Leukemia | Phase 1 / Phase 2 | Completed | Novartis Pharmaceuticals | 27 | 2012-01-09 | 2020-12-30 |
| Short Term Intensified Chemo-immunotherapy in HIV-positive Patients With Burkitt Lymphoma Induction Phase, Consolidation Phase (on day +50), Intensification phase - HIV, Burkitt's Lymphoma | Phase 2 | Completed | Andres J. M. Ferreri | 19 | 2011-11-01 | 2022-08-04 |
| MLN8237 in Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated With Rituximab +/- Vincristine Alisertib (MLN8237), Rituximab, Vincristine - Diffuse Large B-Cell Lymphoma, Transformed Follicular Lymphoma | Phase 1 / Phase 2 | Completed | Millennium Pharmaceuticals, Inc. | 45 | 2011-08-09 | 2018-03-27 |
| Imexon for Relapsed Follicular and Aggressive Lymphomas Imexon - Follicular Lymphoma, Small Lymphocytic Lymphoma | Phase 2 | Completed | University of Rochester | 22 | 2011-05-01 | 2016-01-06 |
| Observational Study for the Cytofluorimetric Analysis of Cerebrospinal Fluid in Non-Hodgkin's Lymphoma Patients Diffuse Large Cell Lymphoma, Lymphoblastic Lymphoma | Completed | Gruppo Italiano Multiregionale per lo studio dei Linfomi e delle Leucemie | 175 | 2009-07-01 | 2013-10-22 | |
| Study of Alisertib (MLN8237) in Adults With Aggressive Non-Hodgkin's Lymphoma Alisertib - Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma | Phase 2 | Completed | Millennium Pharmaceuticals, Inc. | 48 | 2009-02-10 | 2018-03-27 |
| Rapamycin in With High-Dose Etoposide and Cytarabine in Relapsed/Refractory Aggressive Lymphoid Malignancies Rapamycin, High dose etoposide and cytarabine (HiVAC) - ALL, Burkitt's Lymphoma | Phase 1 / Phase 2 | Terminated | Abramson Cancer Center at Penn Medicine | 4 | 2007-01-01 | 2025-11-05 |
| Rituximab Combined With Chemotherapy in Burkitt's Lymphoma RITUXIMAB - Acute Lymphoblastic Leukemia, Burkitt's Lymphoma | Phase 2 | Completed | PETHEMA Foundation | 20 | 2006-08-01 | 2014-10-28 |
| Clofarabine and Cyclophosphamide Combination in Acute Lymphoblastic Leukemia Patients Clofarabine, Cyclophosphamide - Burkitt's Lymphoma, Lymphoblastic Lymphoma | Phase 1 / Phase 2 | Completed | M.D. Anderson Cancer Center | 51 | 2006-03-01 | 2013-03-12 |
| Rituximab and Hyper-CVAD (Cyclophosphamide, Vincristine, Adriamycin, and Dexamethasone) for Burkitt's and Burkitt's -Like Leukemia/Lymphoma Rituximab, Cyclophosphamide, Doxorubicin - Burkitt's Lymphoma, Burkitt'S-like Lymphoma | Phase 2 | Completed | M.D. Anderson Cancer Center | 56 | 2002-08-01 | 2018-05-16 |
Showing 20 of 21. Sign in to see all of them.
Burkitt Lymphoma (21) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (12) · Lymphoma, Mantle-Cell (11) · Leukemia, Lymphocytic, Chronic, B-Cell (9) · Lymphoma, Follicular (9) · Lymphoma, B-Cell, Marginal Zone (8) · Lymphoma, Large B-Cell, Diffuse (8) · Leukemia, Myeloid, Acute (7) · Lymphoma, Non-Hodgkin (6) · Leukemia (5) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (5) · Leukemia, Prolymphocytic (4) · Lymphoma (4) · Multiple Myeloma (4) · Myelodysplastic Syndromes (4)
DNA Virus Infections (21) · Epstein-Barr Virus Infections (21) · Hemic and Lymphatic Diseases (21) · Herpesviridae Infections (21) · Immune System Diseases (21) · Immunoproliferative Disorders (21) · Infections (21) · Lymphatic Diseases (21) · Lymphoproliferative Disorders (21) · Neoplasms (21) · Neoplasms by Histologic Type (21) · Tumor Virus Infections (21) · Virus Diseases (21) · Lymphoma, B-Cell (19) · Lymphoma (17)
Cyclophosphamide (8) · Rituximab (5) · Whole-Body Irradiation (5) · fludarabine (5) · fludarabine phosphate (5) · Cytarabine (4) · Vincristine (3) · Antilymphocyte Serum (2) · Dexamethasone (2) · Doxorubicin (2) · Etoposide (2) · Granulocyte Colony-Stimulating Factor (2) · MLN 8237 (2) · Methotrexate (2) · Mycophenolic Acid (2)
Masonic Cancer Center, University of Minnesota (5) · M.D. Anderson Cancer Center (2) · Millennium Pharmaceuticals, Inc. (2) · ADC Therapeutics S.A. (1) · Abramson Cancer Center at Penn Medicine (1) · Andres J. M. Ferreri (1) · Gachon University Gil Medical Center (1) · Gruppo Italiano Multiregionale per lo studio dei Linfomi e delle Leucemie (1) · Medical College of Wisconsin (1) · Memorial Sloan Kettering Cancer Center (1) · New York Medical College (1) · Nicola Goekbuget (1) · Novartis Pharmaceuticals (1) · PETHEMA Foundation (1) · University of Rochester (1)
United States (16) · Italy (4) · Spain (2) · United Kingdom (2) · Germany (1) · South Korea (1)
Claudio Brunstein, MD (2) · Claudio Brunstein, MD, PhD (1) · Erica Warlick, MD (1) · Jae Park, MD (1) · Margaret MacMillan, MD, MSC (1) · Mary Horowitz, MD, MS (1) · Mitchell S Cairo, MD (1) · Nicola Goekbuget, Dr. med. (1) · Paul M Barr, MD (1) · Selina Luger, MD (1)
PMID 17242396, PMID 25016003, PMID 25359988, PMID 30082475, PMID 31685491, PMID 33211842, PMID 33475736, PMID 34273598, PMID 34515338, PMID 34893942, PMID 37088401, PMID 37120135, PMID 39846144, PMID 39883889, PMID 41350757
2005 (1), 2016 (1), U10HL069294 (1), U24CA076518 (1)